Course Of Coronavirus Infection Research Articles

Control of chronic coronavirus infection in cats with the use of Phosprenyl and Gamavit

Feline enteropathogenic coronavirus affects the intestinal epithelium and causes inflammation of the intestinal mucosa in cats. In adult cats, the infection is usually asymptomatic, but the constant circulation of the coronavirus in the feline population can increase the likelihood of mutation leading to appearance of the virulent strain of the virus that cause feline infectious peritonitis - a deadly disease that develops in 5-10% of cats carrying the coronavirus. The aim of this work was to study the effect of the drugs Phosprenyl and Gamavit on the course of coronavirus infection in cats. A total of 29 cats were monitored. The diagnosis was confirmed by the detection of antibodies by the IHA method, as well as by ultrasound examination of the abdominal organs. Prescribed treatment: Phosprenyl per os, 1 ml , twice a day, course 2-4 months; Gamavit 1 time a day, s/c, course 10 days, with a repeated course after 3 weeks; 3-4 times. As symptomatic therapy, drugs were used to improve the condition of the stool. At the end of treatment, symptoms of gastrointestinal tract damage disappeared in all patients. If before the start of treatment, most patients showed signs of anemia (a decrease in the number of red blood cells and hemoglobin levels), leukocytosis with a predominance of segmented neutrophils, characteristic of infectious and inflammatory processes, and increased ESR, then at the end of therapy, these indicators were completely normalized. Thus, long-term therapy with the use of Phosprenyl and Gamavit helps to control the course of coronavirus infection in cats, prevent its exacerbation and transition to a highly lethal form of infectious peritonitis.

Coronavirus Infection an Obese Patient (Literature Review)

In the modern world the problem of obesity in combination with new coronavirus infection has acquired a special danger. On the one hand, the prevalence of obesity among the population is steadily increasing, on the other-it has been proven that obese people are among the most vulnerable in terms of increased risk of infection and a serious prognosis. This is due to the presence and peculiarities of the development of various pathological mechanisms in this category of patients. These include: high expression of angiotensin-converting enzyme 2, a high probability of a «cytokine storm» developing, maintenance of a chronic inflammatory process in adipose tissue, changes in the activity of Dipeptidyl peptidase-4 enzyme. All these processes lead to an aggravation of metabolic disorders in adipose tissue and violation of immune protection. The world medical practice in the fight against the COVID-19 pandemic shows that patients with coronavirus infection against the background of obesity more often need hospitalization in intensive care units and connection to artificial ventilation equipment. Currently, many features of the course of coronavirus infection against the background of obesity have been identified and continue to be studied. These include: the presence of severe respiratory failure, a high risk of developing respiratory distress syndrome, thrombosis and thromboembolic complications, as well as worsening of the course of chronic cardiovascular diseases. All this eventually leads to the development of severe multiple organ failure, which is often the cause of death in this category of patients.

Influence of SARS-CoV-2 acute respiratory viral disease on pregnancy and childbirth

Acute Respiratory Viral Disease SARS - CoV2 - 19 is a new poorly understood disease with an unpredictable course. This article is devoted to the analysis of coronavirus disease and its impact on the condition of newborns.The objective: to identify and investigate the relationship between the detected and revealed SARS-CoV-2 disease and the course of pregnancy and childbirth, dependence on the term in which the diagnosis was established and the consequences of the disease on the course of pregnancy, childbirth and the condition of newborns; to investigate the frequency of detected complications during pregnancy and the peculiarities of the course of pregnancy with combined pathology.Materials and methods. We analyzed 57 stories of pregnancy and childbirth of women who were admitted to the Uzhgorod City Maternity Hospital in the period from May 2020 to January 2021 with a positive result of the SARS-CoV-2 PLR study.Results. Of 57 patients, pregnancy is ongoing in 18 women, and in 39 it has already ended. Of these, 17 (29.8%) women had vaginal physiological childbirth, 21 (36.8%) women had pathological course of labor, of which 16 (28%) patients underwent cesarean section. In general, 34 pregnant women (59.6%) were asymptomatic. A mild course of the disease was in 20 pregnant women (35%), and a severe course was in three patients (5.2%). As a result of 39 births, 41 children were born (two biochorial twins). Of these, 38 children were born alive (92.7%), stillborn - 4 (5.3%). 31 children were born on time (81.6%). The physiological course of the early neonatal period was observed in all full-term newborns. Perinatal loss was observed in three women at 23, 25 and 28 weeks.Conclusions. In children born of mothers with COVID-19, there was no increase in the frequency of the pathological course of the early neonatal period or detected signs of acute respiratory viral infection. It was also found that there is no clear correlation between the severity of the course of coronavirus infection and complications in pregnant women. So, with a relatively easy mile, even an asymptomatic course, threatening complications were observed, since premature detachment of a normally located placenta was evident, but there was no clear correlation between coronavirus, while with a moderate course of pregnancy, we observed a fairly good result of delivery. The sample of patients is very small and does not allow us to draw definitive conclusions about the effect of coronavirus on pregnancy and fetal health. But these data give us the basis for the next studies on the influence of the new SARS-CoV-2 virus on the course of the gestational process, childbirth and the condition of newborns.

Diabetes mellitus in combination with COVID-19: modern views on therapy

Diabetic patients are in the spotlight from the early stages of a pandemic, as growing epidemiological data show they are at higher risk for severe clinical outcomes from COVID-19. As the global COVID-19 pandemic continues to evolve, it is also becoming increasingly apparent that the interactions between COVID-19 and diabetes mellitus (DM) are complex pathophysiological mechanisms. The outcome of COVID-19 is more severe in people with DM, which has the potential to accelerate the onset of acute metabolic complications of DM such as diabetic ketoacidosis and hyperglycemia. These mechanisms underlying these associations remain unclear, but they likely include the angiotensin converting enzyme receptor 2, a binding site for SARS-CoV-2, which is expressed in key metabolic organs such as in the pancreas, in particular in β-cells. The potential β-cell tropism of SARS-CoV-2 can damage cells and impair insulin secretion, causing hyperglycemia and ketoacidosis. Understanding the bidirectional interaction between DM and COVID-19 will be critical to protecting and treating people with DM. Current epidemiological data on COVID-19 do not support the hypothesis that diabetic patients are at increased risk of infection compared to the general population. To date, it has been established that decompensated DM is an independent factor that aggravates the course of coronavirus infection and significantly increases the risk of a fatal outcome of the disease. The review provides a brief summary of the evolution of pathogenetic and clinical aspects for understanding the mechanisms of this pathological tandem, as well as therapeutic strategies for treating patients with COVID-19 and DM. As the incidence of DM continues to rise globally, more than ever, diabetes prevention and control must be a priority for health systems around the world.

Problem issues of the pathogenesis of inflammatory reaction and the course of coronavirus infection

Objective — to analysis and systematization of literature data about pathogenesis of the inflammatory reaction and the clinical course of coronavirus infection caused by SARS-CoV-2.
 Materials and methods. Access to various full-text and abstract databases was used for the search query «coronavirus», «COVID-19», «SARS-CoV-2» and their systematic evaluation was carried out. The most complete database of available literature sources (about 70) was obtainedon the molecular pathophysiology of COVID-19.
 Results and discussion. The results of the analysis of the molecular pathophysiology of COVID-19 showed that the biomedical terms associated with COVID-19/SARS-CoV-2 form several clusters: cluster 1 is inflammation and the formation of a cytokine storm; cluster 2 — pathophysiological justification of the treatment of coronavirus infection, cluster 3 — comorbid conditions. Analytics of cluster 1 showed one of the most interesting working hypotheses today is model of bradykinin storm. This hypothesis can explain the multisymptomatic nature of COVID-19, including some of its strangest manifestations. The essence of the theory of bradykinin is that, when the virus begins to affect the regulation of renin-angiotensin-aldosterone system (RAAS) through the activation of angio­tensin-converting enzyme type II, it causes the mechanisms that regulate bradykinin levels to fail. Bradykinin’s receptors repeatedly are sensitized and the body also ceases to efficiently break down bradykinin. ACE break down bradykinin, but when the virus suppresses its activity, it cannot work with the same efficiency. The end result of such an imbalance is the release of excessive amounts of bradykinin, due to its mass unrestrained accumulation with the formation of a phenomenon — bradykinin storm. According to the bradykinin hypothesis, this particular variant of the storm is ultimately responsible for the polymorbidity of the clinical picture and the fatal effects cause d by COVID-19.
 Conclusions. The bradykinin hypothesis of the development of a systemic inflammatory response in SARS-CoV-2 virus is a model that contributes to a better understanding of the pathogenesis and course of COVID-19 and adds novelty to data that are already known. It predicts almost all known symptoms today and offers quality treatments for the disease. Analysis of the processed data from the literature of cluster 2, devoted to the pathophysiological rationale treatment of coronavirus infection led to the role of vitamin D — as a nutrient involved in regulatory processes with participation of RAAS.

GENDER DIFFERENCES IN THE COURSE OF SARS COV-2-19 ACUTE RESPIRATORY VIRAL DISEASE

The aim: to analyze and evaluate the relationship between the course of coronavirus infection and the sex of the patient, the presence of comorbidities and their impact on the course of coronavirus disease.Materials and methods. We processed 50 case histories of patients admitted to the Regional Clinical Infectious Diseases Hospital of Uzhhorod in December 2020 and January 2021 with a diagnosis of "Other viral pneumonia, 2019 nCoV acute respiratory disease".Results. Among the patients included in the study group were 26 (52%) women and 24 (48%) men. Of these, the course of moderate disease was observed in 46 patients (93%) and 4 patients (7%) had severe coronavirus infection. 15 patients (30%) out of 50 underwent maintenance oxygen therapy, including non-invasive mechanical ventilation. Among these patients, 6 were women and 9 were men.Conclusions. Acute respiratory viral disease SARS-CoV2-19 in women and men is basically the same, but there are some differences. For example, in our study, the need to hospitalize women was more common than men. This may be due to the psychology of women and men – women are more likely to see a doctor and monitor their health and well-being more closely.

HYPERGLYCEMIA ON THE BACKGROUND OF TREATMENT OF COVID-19-ASSOCIATED PNEUMONIA USING GLUCOCORTICOIDS

The pandemic of coronavirus pneumonia caused by SARS-CoV-2 virus and its multiple complications are a global issue of the day. Coronavirus infection is more severe in patients having chronic concomitant diseases. Also, cardiovascular and metabolic complications, as well as autoimmune disorders, are frequently revealed. The article provides a review of studies regarding hyperglycemia on the background of glucocorticoids use in patients without previous disorders of carbohydrate metabolism. The mechanisms of hyperglycemia development against the background of pathogenetic therapy of cytokine storm in COVID-19 have been described. The aim of this article was to study the pathophysiology of hyperglycemia and to identify hyperglycemia as one of the frequently detected side effects of glucocorticoid treatment against the background of COVID-associated pneumonia. The article presents data from several international research groups about effective and adequate ways of correcting hyperglycemia in accordance with the duration of action of particular insulin medications. The severity of coronavirus infection is often associated with the glycemic status, and this indicator is correlated with the prognosis of the course of coronavirus infection. The biomarkers of inflammatory processes in COVID-19 are discussed. The present article specifies glycemic targets in case of hyperglycemia during treatment with glucocorticoids in the setting of COVID-19.

Pneumomediastinum in patients with a novel coronavirus infection (COVID-19)

To determine the optimal management of pneumomediastinum in patients with a novel coronavirus infection (COVID-19). There were 14 patients with pneumomediastinum and COVID-19 infection without mechanical ventilation. We discussed the world data on pneumomediastinum in patients with coronavirus infection. Before the COVID-19 pandemic, the annual number of own observations of spontaneous pneumomediastinum did not exceed 1-2 patients. The mechanism of pneumomediastinum is explained by the Macklin effect. COVID-19 pandemic in the Russian Federation was followed by increase of the number of patients with pneumomediastinum up to 2.4% of the total number of patients in the thoracic department. In this sample, pneumomediastinum occurred at all variants of the course of coronavirus infection. The timing of pneumomediastinum ranged from 2 to 18 (median 14) days after clinical manifestation of COVID-19. In 2 out of 14 cases, pneumomediastinum was the main symptom of coronavirus infection at admission. One patient had a combination of pneumomediastinum and pneumothorax. In 6 cases, pneumomediastinum was stable and regressed under conservative therapy. Eight patients underwent Razumovsky suprajugular mediastinotomy. There were no postoperative deaths. Recurrent pneumomediastinum was noted in one patient. The causes of pneumomediastinum in some patients with coronavirus infection, peculiarities of diagnosis and treatment and clarification of indications for invasive interventions require further study.

The case of extremely severe course of coronavirus infection in a pregnant woman

The case of extremely severe course of coronavirus infection in a pregnant woman

Androgens and Antiandrogens influence on COVID-19 disease in men

The WHO has declared a SARS-CoV-2 pandemic. During a pandemic, the researches aimed at finding the new treatments for SARS-CoV-2 become relevant. The review focuses on studies of androgens and antiandrogens in this disease. Since the beginning of the COVID-19 epidemic, it has been noted that men have more severe forms of infection and higher mortality. The main cause of both the severity of the disease and the high mortality of men from COVID-19 are associated with androgens. It was found that patients receiving androgen deprivation are less likely to become infected and easily tolerate COVID-19. The researchers explain the effect of the therapy by the effect on the TMPRSS2 protein. It was found that both TMPRSS2 expression and a more severe course of coronavirus infection are observed in men with hyperandrogenism - androgenic alopecia, acne, excessive facial hair growth and increased skin oiliness. In this regard, some researchers suggest to use androgen deprivation for men at high risk of developing COVID-19. Steroid and non-steroidal antiandrogens are used for androgen deprivation. At the same time, obtaned scientific data on the relationship of severe forms and mortality of COVID-19 with low testosterone levels leads to a hypothesis about the possibility of a positive effect not of androgen devrivation therapy but of androgen replacement therapy in case of hypogonadism have diagnosed. These studies have not been completed recently, and data on the effectiveness and safety of antiandrogens and androgens in the treatment of a new coronavirus infection require clarification.

COVID-19 Pneumonia in Patients with Chronic Myocarditis (HBV-Associated with InfarctLike Debute): Specifics of the Diseases Course, the Role of the Basic Therapy (Part II)

Chronic infectious-immune myocarditis of severe course can potentially be considered as a factor that aggravates the course of new coronavirus disease (COVID-19) and increases the risk of adverse outcomes. The interaction of chronic myocarditis and COVID-19 during long-term immunosuppressive therapy has not been studied. We present a description of a 35-year-old female patient with chronic infectious-immune myocarditis (morphologically confirmed, with a history of infarction-like onset and thromboembolic complications), who had continuous immunosuppressive therapy with methylprednisolone and mycophenolate mofetil. The patient also received new oral anticoagulants and tenofovir (for chronic HBV infection). COVID-19 (SARS-Cov-2 RNA+) was diagnosed in May 2020. Risk factors for the adverse course of coronavirus infection included severe obesity, heart failure, and life-threatening ventricular arrhythmias. Correction of immunosuppressive therapy (withdrawal of the cytostatic agent, administration of hydroxychloroquine) and therapy with levofloxacin, an interleukin-17 inhibitor (netakimab) were performed. The severity of pneumonia and respiratory failure was moderate despite high fever and high levels of inflammatory markers in the blood (including interleukin-6). Signs of exacerbation of myocarditis, increased levels of troponin T and anticardial antibodies (compared with the initial ones) were not found. It can be assumed that supportive immunosuppressive therapy for myocarditis has a positive effect on the course of coronavirus pneumonia and avoids exacerbation of myocarditis. Careful continuation of immunosuppressive therapy with temporary withdrawal of aggressive cytostatics can be recommended in chronic myocarditis. Further study of the features of the course of previous myocarditis and COVID-19 pneumonia is necessary.

ВЛИЯНИЕ АНДРОГЕННОГО СТАТУСА И АНТИАНДРОГЕННОЙ ТЕРАПИИ НА ТЕЧЕНИЕ COVID-19 У МУЖЧИН

The WHO has declared a SARS-CoV-2 pandemic. During a pandemic, the researches aimed at finding the new treatments for SARS-CoV-2 become relevant. The review focuses on studies of androgens and antiandrogens in this disease. Since the beginning of the COVID-19 epidemic, it has been noted that men have more severe forms of infection and higher mortality. The main cause of both the severity of the disease and the high mortality of men from COVID-19 are associated with androgens. It was found that patients receiving androgen deprivation are less likely to become infected and easily tolerate COVID-19. The researchers explain the effect of the therapy by the effect on the TMPRSS2 protein. It was found that both TMPRSS2 expression and a more severe course of coronavirus infection are observed in men with hyperandrogenism – androgenic alopecia, acne, excessive facial hair growth and increased skin oiliness. In this regard, some researchers suggest to use androgen deprivation for men at high risk of developing COVID-19. Steroid and non-steroidal antiandrogens are used for androgen deprivation. At the same time, obtaned scientific data on the relationship of severe forms and mortality of COVID-19 with low testosterone levels leads to a hypothesis about the possibility of a positive effect not of androgen devrivation therapy but of androgen replacement therapy in case of hypogonadism have diagnosed. These studies have not been completed recently, and data on the effectiveness and safety of antiandrogens and androgens in the treatment of a new coronavirus infection require clarification.

Non-invasive assessment of skin microcirculation in patients with COVID-19: three clinical cases

Currently, there is enough data to suggest a significant role of microcirculation abnormalities in the pathophysiology of COVID-19. However, no clinical studies on noninvasive assessment of blood microcirculation in patients with the new coronavirus infection have been performed. We measured skin microcirculation by laser Doppler flowmetry in the thermal and inspiratory gasp tests in 3 patients with various courses of COVID-19. A decrease in the skin microcirculation reactivity was found in a patient with a more severe course of coronavirus infection. We believe that assessment of skin microcirculation could become a promising tool for the development of new diagnostic approaches and in future of new treatments for patients with coronavirus infection, as well as for identification of patient categories with a high risk of its severe course. Further studies are required to evaluate the clinical applicability of laser Doppler flowmetry for assessment of skin microcirculation in patients with COVID-19.

COVID-19 Pneumonia in Patients with Chronic Myocarditis (Recurrent Infectious Immune): Specifics of the Diseases Course, the Role of Basic Therapy (Part 1)

Patients with chronic myocarditis have a high risk of an unfavorable course of the novel coronavirus disease (COVID-19) due to the ability of the SARS-Cov-2 virus to independently cause acute myocarditis, to have a direct and cytokine-mediated cytopathic effect on the myocardium, as well as immunosuppressive therapy. At the same time, the features of the interaction of chronic myocarditis and COVID-19 have not been studied. The article describes a 31-year-old patient with a 10-year history of chronic recurrent infectious-immune myocarditis, who was on long-term immunosuppressive therapy (methylprednisolone and azathioprine in the past, then hydroxychloroquine). In May 2020, a serologically confirmed COVID-19 diagnosis was made. There were risk factors for the unfavorable course of coronavirus infection: heart failure and a history of persistent atrial fibrillation, male sex. Basic therapy with hydroxychloroquine (with an increase in its dose to 800-400 mg/day), ceftriaxone, and levofloxacin was carried out. The severity of pneumonia was moderate, despite febrile fever and severe intoxication. No relapses of arrhythmias, respiratory or heart failure were observed. Minimal laboratory (some increase in anticardial antibody titers) and echocardiographic signs of exacerbation of myocarditis without an increase in troponin T levels were revealed, which quickly regressed. It can be assumed that the maintenance immunosuppressive therapy of myocarditis with hydroxychloroquine had a positive effect on the course of coronavirus pneumonia and made it possible to avoid recurrence of myocarditis. Further study of the features of the course of the pre-existing myocarditis and pneumonia in COVID-19 is necessary.

COVID‑19 mathematical forecasting in the Russian Federation

A new coronavirus infection (CVI) is a challenge to the medical system of the Russian Federation and requires precise flow forecasting to take the necessary measures on time. The article provides an overview of modern mathematical tools for predicting the course of CVI in the world. The created CVI forecasting project office allowed to determine the most effective analysis tools in the Russian Federation — the ARIMA, SIRD and Holt–Winters exponential smoothing models. Implementation of these models allows for prediction of short-term morbidity, mortality and survival of patients with an accuracy of 99 % both in the Russian Federation in general and in the regions. In addition, the distribution of CVI was characterized. Particularly, Moscow and Moscow region have the maximum spread of infection, and other regions are lagging behind in the dynamics of the incidence by 1–3 weeks. The obtained models allow us to predict the course of the disease in the regions successfully and take the necessary measures in a timely manner.

Clinically suspected myocarditis in the course of coronavirus infection.

Clinically suspected myocarditis in the course of coronavirus infection.

КОРОНАВИРУСНАЯ ИНФЕКЦИЯ У ДЕТЕЙ

Currently, 7 coronaviruses that cause human disease are known, 3 of which over the past 20 years have caused epidemics with a large number of severe cases, a high mortality rate and infection from the primary focus to other countries, followed by the formation of epidemic foci. The last The last epidemic of coronavirus infection (CVI) COVID-19 (COrona VIrus Disease 2019) arose at the end of December 2019 in the province of Hubei, China and still continues. Objective of the research: comparative epidemiological and clinical characteristics of the new CVI and peculiarities of its course in children. An analysis of 64 publications in in peer-reviewed journals and official sources of health care in Russia and China, WHO, devoted to epidemiologically significant CVI, including COVID-19. According to the literature, in all three epidemics of CVI, children, including newborns, were involved in the epidemic process. Almost all sources indicate a milder course of CVI in young children. Cases of perinatal infection are described. The review provides a comparative analysis of the clinical and epidemiological features of CVI in children using SARS, MERS as an example, gives basic approaches and recommendations for the diagnosis and treatment of COVID-19 with an assessment of the possibility of using antiviral drugs in children.

COVID-19 – rekomendacje dla alergologów i laryngologów

Ostra choroba układu oddechowego COVID-19 ze względu na skalę zjawiska (pandemia) stanowi wyzwanie dla współczesnej medycyny i zdrowia publicznego. Tworzone rekomendacje (w różnych obszarach medycyny, w tym w alergologii) stanowią dla lekarzy i pracowników ochrony zdrowia wskazówki dotyczące właściwego postępowania w zaistniałej sytuacji epidemiologicznej.Każdy pacjent z podejrzeniem infekcji koronawirusem musi mieć przeprowadzone badanie PCR w kierunku SARS-CoV-2 (wymaz z nosogardła). Szczyt wydzielania wirusa pojawia się od 3 do 5 dni. Należy pamiętać, że przebieg infekcji koronawirusowej najczęściej jest łagodny. U chorych z łagodnym przebiegiem zakażenia (bez cech zapalenia płuc), bez zaostrzenia choroby alergicznej, należy kontynuować leczenie choroby podstawowej i ściśle monitorować pacjenta. Zaleca się kontynuowanie leczenia przeciwzapalnego wziewnymi glikokortykosteroidami, ale powinny być one stosowane w postaci ciśnieniowych inhalatorów typu MDI lub inhalatorów proszkowych typu DPI. Eksperci zalecają udzielanie porad lekarskich tylko pacjentom wymagającym pilnej interwencji i podkreślają konieczność stosowania ochrony osobistej.

New coronavirus infection COVID-19: clinical and prognostic significance of plasma fibrinogen level

COVID-associated coagulopathy is currently widely discussed in the medical press. There are no unambiguous ideas about its mechanisms and significance at the present time. One of the manifestations is hyperfibrinogenemia. The study of specific changes in this laboratory indicator is of interest from the point of view of evaluating the prognosis of the course of coronavirus infection and selecting therapy. Objectives. Analysis of plasma fibrinogen dynamics in patients with COVID-19, assessment of clinical and prognostic significance of the indicator. Materials and methods. The retrospective study included 350 patients undergoing inpatient treatment for SARS-CoV-2 infection. At the time of analysis, 49 patients (14 %) died, and the rest were discharged from the hospital. The dynamics of fibrinogen content was evaluated, compared with the outcomes of the disease, clinical complications of a thrombotic or hemorrhagic nature, and other laboratory indicators. Results and conclusion. A characteristic feature of COVID-associated coagulopathy is hyperfibrinogenemia (the maximum value of fibrinogen is 6.2 ± 1.7 g/l) as a manifestation of systemic inflammation with a transition in 14 % of patients to hypofibrinogenemia (the minimum value is 1.57 ± 0.29) due to hepatic dysfunction and consumption coagulopathy. In the context of pharmacological antithrombotic prevention, hyperfibrinogenemia did not show clinical significance as a risk factor for thrombosis, while a decrease in fibrinogen less than 2.0 g/l was associated with a 9-fold increase in the risk of hemorrhagic complications in patients with coronavirus infection (OR 9.913 СI 95 % [1.613–60.931]). A decrease in fibrinogen below normal values and an excess of 9.0 g/l are equally predictors of an adverse outcome in patients with COVID-19. The relative risk of death was 3.263 СI 95 % (1.970–5.407) and 2.574 СI 95 % (1.265–5.237), respectively.

Изменение уровня антител класса IgG к коронавирусу SARS-CoV-2 (COVID-19) у населения регионов Российской Федерации и в динамике у реконвалесцентов

Materials and methods. The article presents the results of laboratory tests for the presence of IgG antibodies to the SARS-CoV-2 coronavirus in 2112 patients living in 5 regions of the Russian Federation. In the main group of the study, 50 people were under dynamic observation for 6 months. Depending on the severity, the main group was divided into two subgroups: group I1 (n=25), represented by patients with moderate coronavirus infection, and group I2 (n=25), consisting of patients with a severe course of coronavirus infection. Blood sampling was carried out on the 14th day of illness (from the moment the first symptoms appeared) in the conditions of the procedure room of the Infectious Diseases Clinical Hospital №1, subsequent blood sampling (44 and 74 days, 3–6 months). Results. During a three-month observation of patients in the main group, there were no significant changes in the content of IgG antibodies to the SARS-CoV-2 coronavirus, and all fluctuations were characterized only by a trend. By the 4th month of observation, the decrease in antibody titer relative to the maximum level (as a rule, 14–44 days) was 43.3% in subgroup I1, and 37.6% in subgroup I2. By the 5th month, the level of IgG antibodies to the SARS-CoV-2 coronavirus in sub-group I1 was 40.9% relative to the maximum value (on day 44), and in subgroup I2 – 35.0% relative to the maximum value (on day 14). After 6 months from the start of observation, the content of IgG antibodies to the SARS-CoV-2 coronavirus in both groups did not differ significantly from the control (p>0,05). Conclusion. We found that there were no significant changes in the level of IgG antibodies to the SARS-CoV-2 coronavirus from the 14th day of illness to the 3rd month of observation from the moment of the first symptoms of the disease. Starting from the 4th month of observation, the level of antibodies decreased in both groups by multiples in relation to the maximum values, decreasing by the 6th month of observation to the values of the control group.